MULTI-ARM POLYMER PRODRUGS
    4.
    发明申请
    MULTI-ARM POLYMER PRODRUGS 有权
    多臂聚合物原料

    公开(公告)号:US20100152414A1

    公开(公告)日:2010-06-17

    申请号:US12709800

    申请日:2010-02-22

    IPC分类号: C08G73/10

    摘要: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

    摘要翻译: 本文提供水溶性前药。 本发明的前药包含具有三个或更多个臂的水溶性聚合物,其中至少三个共价连接到活性剂例如小分子上。 由于本发明的共轭物具有三种或更多种可释放地连接到多臂水溶性聚合物上的活性剂,本发明的共轭物提供聚合物尺寸和结构的最佳平衡以实现改善的药物负载。 与未修饰的母体药物相比,本发明的前药在治疗上是有效的,并且在体内表现出改善的性质。

    Multi-arm polymer prodrugs
    5.
    发明授权
    Multi-arm polymer prodrugs 有权
    多臂聚合物前药

    公开(公告)号:US08318145B2

    公开(公告)日:2012-11-27

    申请号:US12728072

    申请日:2010-03-19

    IPC分类号: A61K31/74

    摘要: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

    摘要翻译: 本文提供水溶性前药。 本发明的前药包含具有三个或更多个臂的水溶性聚合物,其中至少三个共价连接到活性剂例如小分子上。 由于本发明的共轭物具有三种或更多种可释放地连接到多臂水溶性聚合物上的活性剂,本发明的共轭物提供聚合物尺寸和结构的最佳平衡以实现改善的药物负载。 与未修饰的母体药物相比,本发明的前药在治疗上是有效的,并且在体内表现出改善的性质。

    Multi-arm polymer prodrugs
    7.
    发明申请
    Multi-arm polymer prodrugs 审中-公开
    多臂聚合物前药

    公开(公告)号:US20080194612A1

    公开(公告)日:2008-08-14

    申请号:US12069727

    申请日:2008-02-11

    IPC分类号: A61K47/48 A61K31/436

    摘要: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

    摘要翻译: 本文提供水溶性前药。 本发明的前药包含具有三个或更多个臂的水溶性聚合物,其中至少三个共价连接到活性剂例如小分子上。 由于本发明的共轭物具有三种或更多种可释放地连接到多臂水溶性聚合物上的活性剂,本发明的共轭物提供聚合物尺寸和结构的最佳平衡以实现改善的药物负载。 与未修饰的母体药物相比,本发明的前药在治疗上是有效的,并且在体内表现出改善的性质。

    Multi-arm polymer prodrugs
    10.
    发明授权
    Multi-arm polymer prodrugs 有权
    多臂聚合物前药

    公开(公告)号:US07744861B2

    公开(公告)日:2010-06-29

    申请号:US10943799

    申请日:2004-09-17

    IPC分类号: A61K47/48 A61F2/00

    摘要: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

    摘要翻译: 本文提供水溶性前药。 本发明的前药包含具有三个或更多个臂的水溶性聚合物,其中至少三个共价连接到活性剂例如小分子上。 由于本发明的共轭物具有三种或更多种可释放地连接到多臂水溶性聚合物上的活性剂,本发明的共轭物提供聚合物尺寸和结构的最佳平衡以实现改善的药物负载。 与未修饰的母体药物相比,本发明的前药在治疗上是有效的,并且在体内表现出改善的性质。